Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...

With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the ...

Thousands of men with advanced prostate cancer could soon live longer thanks to a treatment which cuts the risk of the ...

Burke was first diagnosed with Stage 2 breast cancer in her late 40s, in March 2024. But shortly after, more tests revealed ...

The coprimary efficacy endpoints were the proportion of patients with a 30% or greater improvement in IPSS from baseline to 3 months and the mean IPSS change from baseline to 12 months. The co-primary ...

Data Supported the FDA Approval of the Zenflow Spring® Implant and Delivery System for BPHAdditional presented data highlights patient ...

“Zeldin’s EPA To Relax Drinking Water Rules” was the headline this week in the daily newspaper Newsday on Long Island, New York—from which Lee Zeldin, the administrator of the U.S. Environmental ...